title: The effect of epoprostenol on platelet activation and consumption during experimental extracorporeal perfusion.
abstract: Hemorrhages are major complications experienced in 10-35% of neonates treated with extracorporeal life support (ECLS). The increased bleeding tendency is partly due to an ECLS induced thrombocytopenia and impaired platelet function. In the present study, we evaluated the effect of epoprostenol on the ECLS induced platelet consumption and activation. In terms of the methods, identical in vitro ECLS circuits were primed with fresh heparinized human blood and circulated for 24 h. Epoprostenol (2.4 microg/L blood/h) was added to one of the circuits in each pair. In total, 6 paired experiments were performed. The platelet count, neutrophil count, plasma concentration of hemoglobin, and platelet membrane expression of glycoproteins (GP) Ib and IIb/IIIa were assayed before the start and at 0.5, 1, 3, 12 and 24 h of perfusion. Higher platelet counts were observed in the experimental circuits. However, no difference in the platelet membrane expression of GPIb and GPIIb/IIIa could be observed between the circuits. In conclusion, epoprostenol reduces platelet consumption during ECLS without affecting the membrane expression of GPIb and GPIIb/IIIa.
authors.affiliation: Department of Pediatrics, Sahlgrens University Hospital, University of Göteborg, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Skogby
authors.forename: K
authors.initials: K
authors.lastname: Adrian
authors.forename: L
authors.initials: L
authors.lastname: Friberg
authors.forename: K
authors.initials: K
authors.lastname: Mellgren
mesh_terms: D000704:Analysis of Variance; D001792:Blood Platelets / Q000187:drug effects*; D011464:Epoprostenol / Q000494:pharmacology*; D015199:Extracorporeal Membrane Oxygenation; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007958:Leukocyte Count; D009504:Neutrophils / Q000473:pathology; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000032:analysis; D013921:Thrombocytopenia / Q000503:physiopathology
chemical_list: D006454:Hemoglobins; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; D011464:Epoprostenol